Well, that's hard to say, as most of the drugs, either directly or indirectly, effect tumor cell survival in the end, which is also influenced by the tumor entity.

In our case, we saw effects on proliferation and/or migration/invasion when we treated GBM cells with bevazizumab or erlotinib in our specific experimental settings.

You might have a look here:

Article EphrinB2 repression through ZEB2 mediates tumour invasion an...

Article Loss of PHD3 allows tumours to overcome hypoxic growth inhib...

I agree with Sascha, there are also the newer drugs called the check point antibody inhibitors such as the PD-1/PDL-1 and CTLA-4 that per se do not kill the cancer cells but help the immune cells to ultimately kill the tumor cells. Also most of the RNAi do not directly kill but silence genes or MDR-1 pump that would ultimately lead to better cancer therapy and cancer cell death/progression/invasion.

Sascha Seidel Arun Iyer Thanks for these replies, it really helps to my consideration.

I think that there are many (significant) candidate molecules were eliminated in the past because of no effect on cell survival in cancer cells. Maybe we should change our frame of mind as a scientist through evaluation of their activities. So I am open to other opinions on this issue. Kind regards..